This study is testing a drug called mezagitamab for adults with IgA nephropathy (IgAN), a kidney condition where immune system proteins build up and can damage the kidneys. You might be able to join if you are an adult with IgAN and have certain levels of protein in your urine (UPCR greater than or equal to 0.8 g/g or urine protein excretion greater than or equal to 1 g/day). The main goal is to see how well mezagitamab changes protein levels in your urine compared to a placebo (a substance that looks like medicine but has no active ingredients). Researchers also want to understand how safe mezagitamab is and how well people can tolerate it. The study is currently recruiting, with a planned enrollment of 347 participants.

Study design

This interventional study will compare mezagitamab injections to placebo injections in adults with IgA nephropathy. It plans to enroll 347 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures changes in proteinuria up to Week 36.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.